SFMBT1 抗体 (AA 816-866)
Quick Overview for SFMBT1 抗体 (AA 816-866) (ABIN1934164)
抗原
See all SFMBT1 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 816-866
- 
                                            特异性
- Region between residue 816 and 866 of human Scm-like with Four mbt Domains 1 using the numbering given in entry NP_057413.2 (GeneID 51460).
- 
                                            纯化方法
- Immunoaffinity purified
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- Approved: IP (2 - 10 μg/mg lysate), WB (1:2000 - 1:10000)
- 
                                            说明
- 
                        Target Species of Antibody: Human 
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- Lot specific
- 
                                            缓冲液
- Tris-citrate/phosphate buffer, pH 7-8, 0.09 % sodium azide.
- 
                                            储存液
- Sodium azide
- 
                                            注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            储存条件
- 4 °C
- 
                                            储存方法
- Store at 2-8°C for up to 1 year.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - SFMBT1 (Scm-Like with Four Mbt Domains 1 (SFMBT1))
- 
                                            别名
- SFMBT1
- 
                                            背景
- 
                        Name/Gene ID: SFMBT1
 Synonyms: SFMBT1, Renal ubiquitous protein 1, RU1, SFMBT
- 
                                            基因ID
- 51460
 抗原
- 
                    
 
                                     
                                     
                                    